BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 16303607)

  • 1. Effects of BM-573, a thromboxane A2 modulator on systemic hemodynamics perturbations induced by U-46619 in the pig.
    Tchana-Sato V; Dogné JM; Lambermont B; Ghuysen A; Magis D; Morimont P; Hanson J; D'Orio V; Limet R; Kolh P
    Prostaglandins Other Lipid Mediat; 2005 Dec; 78(1-4):82-95. PubMed ID: 16303607
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of BM-573 [N-terbutyl-N'-[2-(4'-methylphenylamino)-5-nitro-benzenesulfonyl]urea], a dual thromboxane synthase inhibitor and thromboxane receptor antagonist, in a porcine model of acute pulmonary embolism.
    Ghuysen A; Lambermont B; Dogné JM; Kolh P; Tchana-Sato V; Morimont P; Magis D; Hanson J; Segers P; D'Orio V
    J Pharmacol Exp Ther; 2004 Sep; 310(3):964-72. PubMed ID: 15121765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of U-46619 on pulmonary hemodynamics before and after administration of BM-573, a novel thromboxane A2 inhibitor.
    Lambermont B; Kolh P; Dogné JM; Ghuysen A; Tchana-Sato V; Morimont P; Benoit P; Gérard P; Masereel B; Limet R; D'Orio V
    Arch Physiol Biochem; 2003 Jul; 111(3):217-23. PubMed ID: 14972743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro and in vivo pharmacological characterization of BM-613 [N-n-pentyl-N'-[2-(4'-methylphenylamino)-5-nitrobenzenesulfonyl]urea], a novel dual thromboxane synthase inhibitor and thromboxane receptor antagonist.
    Hanson J; Rolin S; Reynaud D; Qiao N; Kelley LP; Reid HM; Valentin F; Tippins J; Kinsella BT; Masereel B; Pace-Asciak C; Pirotte B; Dogné JM
    J Pharmacol Exp Ther; 2005 Apr; 313(1):293-301. PubMed ID: 15626721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological characterization of N-tert-butyl-N'-[2-(4'-methylphenylamino)-5-nitrobenzenesulfonyl]urea (BM-573), a novel thromboxane A2 receptor antagonist and thromboxane synthase inhibitor in a rat model of arterial thrombosis and its effects on bleeding time.
    Dogné JM; Hanson J; de Leval X; Kolh P; Tchana-Sato V; de Leval L; Rolin S; Ghuysen A; Segers P; Lambermont B; Masereel B; Pirotte B
    J Pharmacol Exp Ther; 2004 May; 309(2):498-505. PubMed ID: 14742735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of BM-573, a novel TXA2 synthase inhibitor and receptor antagonist, in a porcine model of myocardial ischemia-reperfusion.
    Kolh P; Rolin S; Tchana-Sato V; Pétein M; Ghuysen A; Lambermont B; Hanson J; Magis D; Segers P; Masereel B; D'Orio V; Dogne JM
    Prostaglandins Other Lipid Mediat; 2006 Mar; 79(1-2):53-73. PubMed ID: 16516810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protamine-heparin-induced pulmonary hypertension in pigs: effects of treatment with a thromboxane receptor antagonist on hemodynamics and coagulation.
    Nuttall GA; Murray MJ; Bowie EJ
    Anesthesiology; 1991 Jan; 74(1):138-45. PubMed ID: 1824742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of BM-573, a novel thromboxane A2 inhibitor, on pulmonary hemodynamics in endotoxic shock.
    Lambermont B; Ghuysen A; Dogné JM; Kolh P; Tchana-Sato V; Morimont P; Benoit P; Gérard P; Masereel B; D'Orio V
    Arch Physiol Biochem; 2003 Jul; 111(3):224-31. PubMed ID: 14972744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiplatelet activity of carnosol is mediated by the inhibition of TXA2 receptor and cytosolic calcium mobilization.
    Lee JJ; Jin YR; Lim Y; Hong JT; Kim TJ; Chung JH; Yun YP
    Vascul Pharmacol; 2006 Sep; 45(3):148-53. PubMed ID: 16916624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Involvement of brain thromboxane A in hypotension induced by haemorrhage in rats.
    Yalcin M; Cavun S; Yilmaz MS; Cengiz F; Savci V
    Clin Exp Pharmacol Physiol; 2005 Nov; 32(11):960-7. PubMed ID: 16405453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BM-520, an original TXA2 modulator, inhibits the action of thromboxane A2 and 8-iso-prostaglandin F2alphain vitro and in vivo on human and rodent platelets, and aortic vascular smooth muscles from rodents.
    Rolin S; Hanson J; Vastersaegher C; Cherdon C; Pratico D; Masereel B; Dogne JM
    Prostaglandins Other Lipid Mediat; 2007 Aug; 84(1-2):14-23. PubMed ID: 17643884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacology of the thromboxane receptor antagonist and thromboxane synthase inhibitor BM-531.
    Dogné JM; Rolin S; de Leval X; Benoit P; Neven P; Delarge J; Kolh P; Damas J; David JL; Masereel B
    Cardiovasc Drug Rev; 2001; 19(2):87-96. PubMed ID: 11484064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coagulation defects and altered hemodynamic responses in mice lacking receptors for thromboxane A2.
    Thomas DW; Mannon RB; Mannon PJ; Latour A; Oliver JA; Hoffman M; Smithies O; Koller BH; Coffman TM
    J Clin Invest; 1998 Dec; 102(11):1994-2001. PubMed ID: 9835625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thromboxane A2 receptor antagonism in man and rat by a sulphonylcyanoguanidine (BM-144) and a sulphonylurea (BM-500).
    Masereel B; Damas J; Fontaine J; Lembege M; Lacan F; Nuhrich A; Delarge J; Pochet L; Dogne JM
    J Pharm Pharmacol; 1999 Jun; 51(6):695-701. PubMed ID: 10454046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel thromboxane receptor antagonist and synthase inhibitor, BM-573, reduces development and progression of atherosclerosis in LDL receptor deficient mice.
    Cyrus T; Yao Y; Ding T; Dogné JM; Praticò D
    Eur J Pharmacol; 2007 Apr; 561(1-3):105-11. PubMed ID: 17306791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BM-573, a dual thromboxane synthase inhibitor and thromboxane receptor antagonist, prevents pig myocardial infarction induced by coronary thrombosis.
    Rolin S; Petein M; Tchana-Sato V; Dogne JM; Benoit P; Lambermont B; Ghuysen A; Kolh P; Masereel B
    J Pharmacol Exp Ther; 2003 Jul; 306(1):59-65. PubMed ID: 12721335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of a novel thromboxane A2 inhibitor on right ventricular-arterial coupling in endotoxic shock.
    Lambermont B; Kolh P; Ghuysen A; Segers P; Dogné JM; Tchana-Sato V; Morimont P; Benoit P; Gérard P; Masereel B; D'Orio V
    Shock; 2004 Jan; 21(1):45-51. PubMed ID: 14676683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Different mechanisms between thromboxane A2- and leukotriene D4-induced nasal blockage in guinea pigs.
    Tanaka Y; Mizutani N; Fujii M; Nabe T; Kohno S
    Prostaglandins Other Lipid Mediat; 2006 Sep; 80(3-4):144-54. PubMed ID: 16939879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platelet antiaggregating activity of ginsenosides isolated from processed ginseng.
    Lee JG; Lee YY; Kim SY; Pyo JS; Yun-Choi HS; Park JH
    Pharmazie; 2009 Sep; 64(9):602-4. PubMed ID: 19827304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological evaluation of the novel thromboxane modulator BM-567 (I/II). Effects of BM-567 on platelet function.
    Dogné JM; de Leval X; Kolh P; Sanna V; Rolin S; Michaux C; Mauer M; David JL; Masereel B; Pirotte B
    Prostaglandins Leukot Essent Fatty Acids; 2003 Jan; 68(1):49-54. PubMed ID: 12538090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.